House Democrats are probing the three main insulin manufacturers in the U.S. over "skyrocketing costs."

Eli Lilly, Novo Nordisk and Sanofi received questions about their pricing strategies from Rep. Frank Pallone Jr. Frank Joseph PallonePharma execs say FDA will not lower standards for coronavirus vaccine Dem chairmen urge CMS to prevent nursing homes from seizing stimulus payments Federal watchdog finds cybersecurity vulnerabilities in FCC systems MORE (D-N.J.), chairman of the powerful Energy and Commerce Committee, and Rep. Diana DeGette Diana Louise DeGette87 lawmakers ask EPA to reverse course after rescinding methane regulations Overnight Health Care: Supreme Court to hear ObamaCare arguments 1 week after election | NYC positive COVID-19 tests hit record low With Biden, advocates sense momentum for lifting abortion funding ban MORE (D-Colo.), chairwoman of the Energy and Commerce Subcommittee on Oversight and Investigations.

Pallone and DeGette said they worry about diabetics rationing their insulin because they can't afford to buy more.

ADVERTISEMENT

“When patients go without insulin—or ration their doses—there can be tragic consequences,” they said in a letter to the drug manufacturers.

"As one of the few manufacturers of insulin in the United States, your company is well-suited to shed light on these issues and offer potential solutions.”

They're asking for a range of documents and information from the companies, including their average price for insulin products for the past 10 years, and explanations for increases; the net profits of the companies' insulin products for the past 10 years; and a list of changes made to their insulin products.

Pallone and DeGette questioned why insulin prices have increased in recent years, despite the lack of significant advances in the formula.

They say the price of insulin tripled between 2002 and 2013, and nearly doubled between 2012 and 2016

They're also asking whether the companies have entered into any agreements in the last 10 years that delay, limit or prevent the availability of generic insulin on the market.

The issue of high drug prices has the potential to prompt bipartisan action in Congress.

Senate Finance Committee Chairman Chuck Grassley Charles (Chuck) Ernest GrassleySenate Republicans face tough decision on replacing Ginsburg What Senate Republicans have said about election-year Supreme Court vacancies Biden says Ginsburg successor should be picked by candidate who wins on Nov. 3 MORE (R-Iowa) said Wednesday during a hearing on drug prices that he wants to investigate spikes in insulin costs.

“I have heard stories about people reducing their life-saving medicines, like insulin, to save money,” Grassley said.

“This is unacceptable and I intend to specifically get to the bottom of the insulin price increase.”